NO314499B1 - Fremgangsmåte for å oppnå enantiomerer av cis-olirtin - Google Patents
Fremgangsmåte for å oppnå enantiomerer av cis-olirtin Download PDFInfo
- Publication number
- NO314499B1 NO314499B1 NO20000560A NO20000560A NO314499B1 NO 314499 B1 NO314499 B1 NO 314499B1 NO 20000560 A NO20000560 A NO 20000560A NO 20000560 A NO20000560 A NO 20000560A NO 314499 B1 NO314499 B1 NO 314499B1
- Authority
- NO
- Norway
- Prior art keywords
- pyrazol
- ketone
- methyl
- phenyl
- chiral
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 44
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title claims description 10
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 150000002576 ketones Chemical class 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000002904 solvent Substances 0.000 claims abstract description 11
- 239000003054 catalyst Substances 0.000 claims abstract description 10
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 10
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000005804 alkylation reaction Methods 0.000 claims abstract description 6
- 229910052796 boron Inorganic materials 0.000 claims abstract description 6
- 238000002955 isolation Methods 0.000 claims abstract description 5
- 230000029936 alkylation Effects 0.000 claims abstract description 3
- 238000000746 purification Methods 0.000 claims abstract description 3
- WQMAANNAZKNUDL-UHFFFAOYSA-N 2-dimethylaminoethyl chloride Chemical compound CN(C)CCCl WQMAANNAZKNUDL-UHFFFAOYSA-N 0.000 claims abstract 5
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 54
- HXGRGBPDHYBBRD-UHFFFAOYSA-N (2-methylpyrazol-3-yl)-phenylmethanone Chemical compound CN1N=CC=C1C(=O)C1=CC=CC=C1 HXGRGBPDHYBBRD-UHFFFAOYSA-N 0.000 claims description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 claims description 4
- ZDQWVKDDJDIVAL-UHFFFAOYSA-N catecholborane Chemical compound C1=CC=C2O[B]OC2=C1 ZDQWVKDDJDIVAL-UHFFFAOYSA-N 0.000 claims description 4
- 230000007704 transition Effects 0.000 claims description 4
- 229910000085 borane Inorganic materials 0.000 claims description 3
- DCMJBKFKXGPPMT-HNNXBMFYSA-N n,n-dimethyl-2-[(s)-(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine Chemical compound C1([C@@H](OCCN(C)C)C=2C=CC=CC=2)=CC=NN1C DCMJBKFKXGPPMT-HNNXBMFYSA-N 0.000 claims description 3
- BDOLXPFAFMNDOK-UHFFFAOYSA-N oxazaborolidine Chemical compound B1CCON1 BDOLXPFAFMNDOK-UHFFFAOYSA-N 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- UYVGFRVKQOCGDA-LLVKDONJSA-N (r)-(2-methylpyrazol-3-yl)-phenylmethanol Chemical compound CN1N=CC=C1[C@H](O)C1=CC=CC=C1 UYVGFRVKQOCGDA-LLVKDONJSA-N 0.000 claims description 2
- DCMJBKFKXGPPMT-OAHLLOKOSA-N n,n-dimethyl-2-[(r)-(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine Chemical compound C1([C@H](OCCN(C)C)C=2C=CC=CC=2)=CC=NN1C DCMJBKFKXGPPMT-OAHLLOKOSA-N 0.000 claims description 2
- DCMJBKFKXGPPMT-UHFFFAOYSA-N n,n-dimethyl-2-[(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=NN1C DCMJBKFKXGPPMT-UHFFFAOYSA-N 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 238000006722 reduction reaction Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 238000004296 chiral HPLC Methods 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- -1 {-)-ethyl Chemical group 0.000 description 3
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001414 amino alcohols Chemical class 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- 229960002303 citric acid monohydrate Drugs 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- OBCUSTCTKLTMBX-VIFPVBQESA-N (2s)-2-acetyloxy-2-phenylacetic acid Chemical compound CC(=O)O[C@H](C(O)=O)C1=CC=CC=C1 OBCUSTCTKLTMBX-VIFPVBQESA-N 0.000 description 1
- LDLRZFBSMOWZOS-HXUWFJFHSA-N (4r)-2-methyl-4,5,5-triphenyl-1,3,2-oxazaborolidine Chemical compound C1([C@H]2NB(OC2(C=2C=CC=CC=2)C=2C=CC=CC=2)C)=CC=CC=C1 LDLRZFBSMOWZOS-HXUWFJFHSA-N 0.000 description 1
- UYVGFRVKQOCGDA-NSHDSACASA-N (s)-(2-methylpyrazol-3-yl)-phenylmethanol Chemical compound CN1N=CC=C1[C@@H](O)C1=CC=CC=C1 UYVGFRVKQOCGDA-NSHDSACASA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- JBYHSSAVUBIJMK-UHFFFAOYSA-N 1,4-oxathiane Chemical compound C1CSCCO1 JBYHSSAVUBIJMK-UHFFFAOYSA-N 0.000 description 1
- ZIELEIJWNRPJIZ-UHFFFAOYSA-N 2-chloro-n,n-dimethylethanamine;hypochlorous acid Chemical compound ClO.CN(C)CCCl ZIELEIJWNRPJIZ-UHFFFAOYSA-N 0.000 description 1
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 1
- FVQDOKQWEOZEBQ-UHFFFAOYSA-N B1NCCO1 Chemical compound B1NCCO1 FVQDOKQWEOZEBQ-UHFFFAOYSA-N 0.000 description 1
- NYYZILVJGBWGEZ-CBAPKCEASA-N C[C@@H]1N=BO[C@@H]1C1=CC=CC=C1 Chemical compound C[C@@H]1N=BO[C@@H]1C1=CC=CC=C1 NYYZILVJGBWGEZ-CBAPKCEASA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 238000005713 Midland reduction reaction Methods 0.000 description 1
- 241000428199 Mustelinae Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 238000010934 O-alkylation reaction Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES009701728A ES2130083B1 (es) | 1997-08-04 | 1997-08-04 | Procedimiento para la obtencion de los enantiomeros de cizolirtina. |
| PCT/ES1998/000223 WO1999007684A1 (es) | 1997-08-04 | 1998-07-31 | Procedimiento para la obtencion de los enantiomeros de cizolirtina |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20000560D0 NO20000560D0 (no) | 2000-02-03 |
| NO20000560L NO20000560L (no) | 2000-03-29 |
| NO314499B1 true NO314499B1 (no) | 2003-03-31 |
Family
ID=8300306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20000560A NO314499B1 (no) | 1997-08-04 | 2000-02-03 | Fremgangsmåte for å oppnå enantiomerer av cis-olirtin |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6118009A (de) |
| EP (1) | EP1029852B1 (de) |
| JP (1) | JP2001512718A (de) |
| AT (1) | ATE227272T1 (de) |
| AU (1) | AU8442698A (de) |
| CA (1) | CA2299447C (de) |
| DE (1) | DE69809282T2 (de) |
| DK (1) | DK1029852T3 (de) |
| ES (2) | ES2130083B1 (de) |
| NO (1) | NO314499B1 (de) |
| PT (1) | PT1029852E (de) |
| WO (1) | WO1999007684A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040142929A1 (en) * | 2001-07-06 | 2004-07-22 | Ramon Merce-Vidal | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence |
| TW200533657A (en) * | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
| EP1584335A3 (de) * | 2004-04-05 | 2006-02-22 | Laboratorios Del Dr. Esteve, S.A. | Zusammensetzung aus Aktiva mit einer Carbinolverbindung und einem Opioid |
| CA2562231A1 (en) * | 2004-04-05 | 2005-10-20 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination of a carbinol compound and an opioid |
| ES2244326B1 (es) * | 2004-04-05 | 2007-02-16 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de substancias activas. |
| US20060040924A1 (en) * | 2004-06-22 | 2006-02-23 | Laboratorios Dr. Esteve S.A. | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of renal colic |
| EP1671953A1 (de) * | 2004-12-17 | 2006-06-21 | Laboratorios Del Dr. Esteve, S.A. | Verfahren zur Herstellung von Cizolirtine und dessen Enantiomeren |
| WO2006063861A1 (en) * | 2004-12-17 | 2006-06-22 | Laboratorios Del Dr. Esteve, S.A. | Process for obtaining cizolirtine and its enantiomers |
| EP1671968A1 (de) * | 2004-12-17 | 2006-06-21 | Laboratorios Del Dr. Esteve, S.A. | Verfahren zur Herstellung von Enantiomeren von Thienylazolylalkoxyethanamines |
| US7897589B2 (en) * | 2005-07-15 | 2011-03-01 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
| EP1757587A1 (de) * | 2005-07-15 | 2007-02-28 | Laboratorios Del Dr. Esteve, S.A. | Substituierte Pyrazolinderivate, ihre Herstellung und Verwendung als Arzneimittel |
| EP1743890A1 (de) | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | 4,5-Dihydro-1H-Pyrazol-Derivative, Verfahren zur Herstellung und ihre Verwendung als Medikamente. |
| EP1743892A1 (de) * | 2005-07-15 | 2007-01-17 | Laboratorios del Dr. Esteve S.A. | Substituierte Pyrazolin Verbindungen, deren Herstellung und Verwendung als Medikament |
| EP1820502A1 (de) | 2006-02-10 | 2007-08-22 | Laboratorios Del Dr. Esteve, S.A. | Wirkstoffzusammensetzungen enthaltend Azolycarbinolderivate |
| EP2151234A1 (de) * | 2008-07-28 | 2010-02-10 | Laboratorios Del. Dr. Esteve, S.A. | Pharmazeutische Formulierung mit einer CB1-Rezeptorverbindung in einer festen Lösung und/oder festen Dispersion |
| WO2010123999A2 (en) * | 2009-04-21 | 2010-10-28 | Auspex Pharmaceuticals, Inc. | 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor |
| DE102010056283A1 (de) | 2010-12-24 | 2012-06-28 | Volkswagen Ag | Wärmeübertragungssystem |
| CN108558695A (zh) * | 2018-05-15 | 2018-09-21 | 浙江华贝药业有限责任公司 | 2，2，2-三氟-n-[(1s，4s)-4-羟基四氢萘-1-基]-乙酰胺制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4943635A (en) * | 1987-08-27 | 1990-07-24 | President & Fellows Of Harvard College | Enantioselective reduction of ketones |
| KR950701637A (ko) * | 1992-05-14 | 1995-04-28 | 알렌 제이. 스피겔 | 에난티오 선택적인 옥사자보롤리딘 촉매(enantioselective oxazaborolidine catalysts) |
| US5442118A (en) * | 1994-04-22 | 1995-08-15 | Sepracor, Inc. | Asymmetric synthesis of (R)- and (S)-arylethanolamines from iminoketones |
-
1997
- 1997-08-04 ES ES009701728A patent/ES2130083B1/es not_active Expired - Fee Related
-
1998
- 1998-07-31 EP EP98935042A patent/EP1029852B1/de not_active Expired - Lifetime
- 1998-07-31 ES ES98935042T patent/ES2187044T3/es not_active Expired - Lifetime
- 1998-07-31 CA CA002299447A patent/CA2299447C/en not_active Expired - Fee Related
- 1998-07-31 DK DK98935042T patent/DK1029852T3/da active
- 1998-07-31 AU AU84426/98A patent/AU8442698A/en not_active Abandoned
- 1998-07-31 PT PT98935042T patent/PT1029852E/pt unknown
- 1998-07-31 US US09/485,023 patent/US6118009A/en not_active Expired - Fee Related
- 1998-07-31 AT AT98935042T patent/ATE227272T1/de not_active IP Right Cessation
- 1998-07-31 JP JP2000506188A patent/JP2001512718A/ja active Pending
- 1998-07-31 DE DE69809282T patent/DE69809282T2/de not_active Expired - Fee Related
- 1998-07-31 WO PCT/ES1998/000223 patent/WO1999007684A1/es active IP Right Grant
-
2000
- 2000-02-03 NO NO20000560A patent/NO314499B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2299447A1 (en) | 1999-02-18 |
| NO20000560D0 (no) | 2000-02-03 |
| DK1029852T3 (da) | 2003-02-24 |
| EP1029852A1 (de) | 2000-08-23 |
| ES2130083B1 (es) | 2000-01-16 |
| AU8442698A (en) | 1999-03-01 |
| ATE227272T1 (de) | 2002-11-15 |
| DE69809282D1 (de) | 2002-12-12 |
| PT1029852E (pt) | 2003-03-31 |
| ES2187044T3 (es) | 2003-05-16 |
| CA2299447C (en) | 2007-05-29 |
| WO1999007684A1 (es) | 1999-02-18 |
| DE69809282T2 (de) | 2003-09-11 |
| EP1029852B1 (de) | 2002-11-06 |
| ES2130083A1 (es) | 1999-06-16 |
| JP2001512718A (ja) | 2001-08-28 |
| NO20000560L (no) | 2000-03-29 |
| US6118009A (en) | 2000-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO314499B1 (no) | Fremgangsmåte for å oppnå enantiomerer av cis-olirtin | |
| JP7085641B2 (ja) | アルコラート塩基の存在下でのニコチン酸エチルとｎ－ビニルピロリドンとの反応によるラセミ体ニコチンの調製方法 | |
| US4943635A (en) | Enantioselective reduction of ketones | |
| Munchhof et al. | An asymmetric route to chiral, nonracemic 2-substituted piperidines. Synthesis of (-)-pipecoline,(+)-coniine, and (-)-coniceine | |
| EP2079706B1 (de) | Verfahren zur herstellung von medetomidin und seinen salzen | |
| EP1971592B1 (de) | Verbesserte synthese und zubereitungen von duloxetinsalzen | |
| IL151533A (en) | History of Amid Cyclic and Sigma Pharmaceuticals and Legends | |
| IE42216B1 (en) | Benzomorphane derivatives | |
| EP2114912B1 (de) | Verfahren zur herstellung von duloxetin und verwandten verbindungen | |
| NZ249302A (en) | 4,5-diphenyl-1,3,2-oxazaborolidine derivatives and their use as catalysts in reduction of ketones to chiral alcohols | |
| US5495054A (en) | Tetrahydroindeno[1,2-D][1,3,2]oxazaboroles and their use as enantioselective catalysts | |
| Panek et al. | Ireland-Claisen rearrangements of chiral (Z)-vinylsilanes. Highly diastereoselective synthesis of anti-. alpha.-alkoxy-. beta.-(dimethylphenylsilyl)-(E)-hex-4-enoates | |
| US4100288A (en) | N-Tetrahydrofurfuryl-noroxymorphones, their salts, and analgesic compositions and methods employing them | |
| CN105693598A (zh) | 一种铱催化氢化合成3-哌啶酮衍生物的方法 | |
| HU213671B (en) | Process for producing novel and known 4-aryl-4-piperidine or pyrrolidine or hexahydroazepine carbinols and pharmaceutical compositions comprising the novel compounds | |
| IL147668A (en) | Process for the preparation of venlafaxin | |
| US7078531B2 (en) | Process for obtaining enantiomers of thienylazolylalcoxyethanamines | |
| FR2495470A1 (fr) | Nouveaux medicaments a base de derives de (quinolyl-4)-1 (piperidyl-4)-2 ethanol ou (quinolyl-4)-1 (piperidyl-4)-3 propanol | |
| Kavanagh et al. | Stereocontrolled preparation of bicyclic alkaloid analogues: an approach towards the kinabalurine skeleton | |
| Clayden et al. | Atroposelective attack of nucleophiles and electrophiles on 2-acyl-1-naphthamides and their enolates | |
| CN108101860A (zh) | 顺式-2，6-二甲基吗啉的制备方法 | |
| US5808088A (en) | Preparation of mibefradil via an acetamide anion | |
| US20060135788A1 (en) | Process for obtaining cizolirtine and its enantiomers | |
| EP1074550A1 (de) | Verfahren zur Herstellung von 3-substituierten 4-Phenyl-Piperidin Derivaten | |
| Hueso-Rodríguez et al. | Preparation of the enantiomers of the analgesic E-3710. |